The IPO market is reopening with conditions attached. Public-market activity is returning selectively in 2026, favoring companies with strong fundamentals instead of rewarding every ambitious growth story that reaches the filing stage.
The market peaked in 2021, when close to 400 companies went public, then slowed as interest rates rose, valuations fell and recession concerns weakened issuance. EY’s 2025 review described 2022 and 2023 as the weakest period since the global financial crisis; activity improved in 2024 and stabilized further in 2025, when 202 IPOs marked the strongest annual result since 2021.
Many companies used that long pause to stay private, raise more capital, build scale and wait for public-market conditions to improve. They had options—companies now have more ways to raise money privately than they did in the past, which makes an IPO a choice rather than an unavoidable milestone.
More IPOs, But a Very Uneven Recovery
The first half of 2026 produced 58 venture-backed companies valued at $1 billion or more going public worldwide, up from 27 in the same period of 2025 and already approaching the 69 recorded across all of last year. Those companies raised $110.8 billion through IPOs, compared with $12.6 billion a year earlier.
That headline number needs an asterisk large enough to list on an exchange. SpaceX contributed $86 billion, nearly 78% of the first-half total, turning an improving market into a market with one enormous outlier attached.
Capital-raising projects rose 32% globally in the first half of 2026 from a year earlier, while IPO-related project kickoffs rose 33%. Yet 2026 has produced about $146.9 billion from 110 IPO deals, excluding SPACs, down 30% from 2025; total IPO proceeds are still up 394% year-to-date.
Health care and industrials each represent 24% of IPOs so far this year, followed by technology at 18%. Fifty-nine percent of all 2026 offerings are selling at or above their IPO price, although SpaceX, SK Hynix and Cerebras are lagging—a reminder that even the market’s favored sectors do not guarantee a clean debut.
Postponements Are Setting the Real Tone
IPO postponements accelerated in 2026. Four companies in different sectors postponed or withdrew offerings during the past week, bringing the third-quarter total to seven, compared with four in the second quarter and three in the first.
Oura Health Oy delayed its IPO on September 29, citing “uncertainty” in market conditions. Bamboo Insurance postponed its offering on September 22, Amaero also postponed on September 22, and Holtec Nuclear withdrew its IPO last Friday before September 29; all four companies had aimed to raise at least $50 million.
“The fact that we’ve had three or four in a row – a string of postponements – I think that does tell you something about the market,” said Matthew Kennedy, senior strategist at Renaissance Capital. The sequence matters because companies do not usually abandon an offering after spending time and money preparing it unless the market’s response threatens the economics of going public.
Jay Ritter, director of the IPO Initiative at the University of Florida’s Warrington College of Business, said, “I’ve got a little bit of sympathy for market conditions as a rationale.” He added, “The fact that three prominent companies are doing this does indicate that it’s not company-specific.”
The pressure comes from several directions: macroeconomic uncertainty, concern about AI buildout, bond yields at a 19-year high and resumed rate hikes. IPO activity in the third quarter of 2026 fell below expectations as investors questioned AI spending and the returns from the infrastructure required to support it.
The Renaissance IPO ETF peaked in June 2026 when SpaceX launched, underscoring how much market enthusiasm has clustered around a small group of high-profile companies. Data centers may have strong demand, Ritter said, but “Things like data centers, there’s big demand there, but it’s largely a commodity business.” Demand alone is not a valuation strategy, despite what a bull market may suggest.
Companies entering the market now need stronger margins, more predictable revenue, cleaner governance, tighter controls and a longer operating record. Investors have seen what happens when a narrow consumer product carries too much of the story: Gil Luria, head of technology research at DA Davidson, said, “I would draw a line [around] Peloton, GoPro, FitBit and Oura. Investors have been burned pretty badly by narrow consumer products, and that is the reaction Oura is getting.”
Oura’s business is concentrated in its biometric ring product, a focus that makes the company easier to understand but leaves less room for weakness in one product category. Tom Hale, CEO of Oura Health Oy, wore an Oura Ring during an interview on Friday, June 14, 2024; two years later, the company’s delayed offering shows that product visibility cannot substitute for market timing.
The 2026 IPO market is open, but selectively. Companies with durable operations can still attract capital; companies relying on excitement, narrow products or expensive AI plans face a colder reception—and the filing calendar is already making that distinction plain.
Based on
